The anti-inflammatory effect of A₃ adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis

Bibliography

• GOLDBACH-MANSKY R, LIPSKY PE: New concepts in the treatment of rheumatoid arthritis. Ann. Rev. Med. (2003) 54:197-216.
   PubMed Web of Science ®Google Scholar
• LEE DM, WEINBLATT ME: Rheumatoid arthritis. Lancet (2001) 358(9285):903-911.
   PubMed Web of Science ®Google Scholar
• O'DELL JR: How is it best to treat early rheumatoid arthritis patients? Best Pract. Res. Clin. Rheumatol. (2001) 15(1):125-137.
   PubMed Web of Science ®Google Scholar
• SCOTT DL, KINGSLEY GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. (2006) 355(7):704-712.
   PubMed Web of Science ®Google Scholar
• HASAN U: TNF inhibitors – what we need to know. N. Z. Med. J. (2006) 119(1246):U2336.
   PubMedGoogle Scholar
• SHARMA PK, HOTA D, PANDHI P: Biologics in rheumatoid arthritis. J. Assoc. Physicians India (2004) 52:231-236.
   PubMedGoogle Scholar
• LINDEN J: Cloned adenosine A3 receptors: pharmacological properties, species differences, and receptor function. Trends Pharmacol. Sci. (1994) 15:298-306.
   PubMed Web of Science ®Google Scholar
• POULSEN S, QUINN R: Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. (1998) 6(6):619-641.
   PubMed Web of Science ®Google Scholar
• PALMER TM, STILES GL: Adenosine receptors. Neuropharmacology (1995) 34(7):683-694.
   PubMed Web of Science ®Google Scholar
• KHOA ND, MONTESINOS MC, REISS AB, DELANO D, AWADALLAH N, CRONSTEIN BN: Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J. Immunol. (2001) 167(7):4026-4032.
   PubMed Web of Science ®Google Scholar
• XAUS J, MIRABET M, LLOBERAS J et al.: IFN-γ up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J. Immunol. (1999) 162(6):3607-3614.
   PubMed Web of Science ®Google Scholar
• XU Z, JANG Y, MUELLER RA, NORFLEET EA: IB-MECA and cardioprotection. Cardiovasc. Drug Rev. (2006) 24(3-4):227-238.
   PubMedGoogle Scholar
• CHEN GJ, HARVEY BK, SHEN H, CHOU J, VICTOR A, WANG Y: Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J. Neurosci. Res. (2006) 84(8):1848-1855.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, FARBSTEIN T, BARER F, OHANA G: Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J. Cell. Physiol. (2000) 183(3):393-398.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, BARER F, MADI L, MULTANI AF, PATHAK S: The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp. Cell. Res. (2001) 269(2):230-236.
   PubMed Web of Science ®Google Scholar
• BAR-YEHUDA S, MADI L, BARAK D et al.: Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation: a new class of myeloprotective agents. Exp. Hematol. (2002) 30(12):1390-1398.
   PubMed Web of Science ®Google Scholar
• MADI L, OCHAION A, RATH-WOLFSON L et al.: The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin. Cancer Res. (2004) 10(13):4472-4479.
   PubMed Web of Science ®Google Scholar
• GESSI S, CATTABRIGA E, AVITABILE A et al.: Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin. Cancer Res. (2004) 10(17):5895-5901.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, MADI L, BAR-YEHUDA S, BARER F, DEL VALLE L, KHALILI K: Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene (2002) 21(25):4060-4064.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, MADI L, COHN I: A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs (2002) 13(5):437-443.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S: Pharmacology and therapeutic applications of A3 receptor subtype. Cur. Top. Med. Chem. (2003) 3(4):463-469.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, ARDON E et al.: Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res. (2003) 23(3A):2077-2083.
   PubMed Web of Science ®Google Scholar
• MADI L, BAR-YEHUD S, BARER F, ARDON E, OCHAION A, FISHMAN P: A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J. Biol. Chem. (2003) 278(43):42121-42130.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, OHANA G et al.: An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 β and NF-κB. Oncogene (2004) 23(14):2465-2471.
   PubMed Web of Science ®Google Scholar
• BAR-YEHUDA S, MADI L, SILBERMAN D, GERY S, SHKAPENUK M, FISHMAN P: CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia (2005) 7(1):85-90.
   PubMed Web of Science ®Google Scholar
• LEE EJ, MIN HY, CHUNG HJ et al.: A novel adenosine analog, thio-Cl-IB-MECA, induces G0/G1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. Biochem. Pharmacol. (2005) 70(6):918-924.
   PubMed Web of Science ®Google Scholar
• CHUNG H, JUNG JY, CHO SD et al.: The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers. Mol. Cancer Ther. (2006) 5(3):685-692.
   PubMed Web of Science ®Google Scholar
• FISHMAN P, BAR-YEHUDA S, MADI L et al.: The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res. Ther. (2006) 8(6):1-9.
   Google Scholar
• SZABO C, SCOTT GS, VIRAG L et al.: Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. (1998) 125(2):379-387.
   PubMed Web of Science ®Google Scholar
• BAHARAV E, BAR-YEHUDA S, MADI L et al.: The anti-inflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. (2005) 32(3):469-476.
   PubMed Web of Science ®Google Scholar
• LINDEN J: New insights into the regulation of inflammation by adenosine. J. Clin. Invest. (2006) 116(7):1835-1837.
   PubMed Web of Science ®Google Scholar
• SULLIVAN GW: Adenosine A2A receptor agonists as anti-inflammatory agents. Curr. Opin. Investig. Drugs (2003) 4(11):1313-1319.
   PubMedGoogle Scholar
• LAPPAS CM, SULLIVAN GW, LINDEN J: Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs (2005) 14(7):797-806.
   PubMed Web of Science ®Google Scholar
• SHIGEKI T, JURGEN S, FARSHID N et al.: A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. (2004) 24:1521-1529.
   PubMed Web of Science ®Google Scholar
• YANG D, ZHANG Y, N GUYEN HG et al.: The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest. (2006) 116:1913-1923.
   PubMed Web of Science ®Google Scholar
• DHALLA AK, WONG MY, WANG WQ, BIAGGIONI I, BELARDINELLI L: Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J. Pharmacol. Exp. Ther. (2006) 316(2):695-702.
   PubMed Web of Science ®Google Scholar
• MADI L, COHEN S, OCHAION A, BAR-YEHUDA S, BARER F, FISHMAN P: Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of NF-κB in mediating receptor level. J. Rheumatol. (2007) 34(1):20-26.
   PubMed Web of Science ®Google Scholar
• GESSI S, VARANI K, MERIGHI S et al.: Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol. Pharmacol. (2004) 65(3):711-719.
   PubMed Web of Science ®Google Scholar
• GUZMAN J, YU JG, SUNTRES Z et al.: ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm. Bowel Dis. (2006) 12(8):766-789.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB, IJZERMANJ AP, JACOBSON KA, KLOTZl KN, LINDEN J: International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. (2001) 53:527-552.
   PubMed Web of Science ®Google Scholar
• VAN TROOSTENBURG AR, CLARK EV, CAREY WD et al.: Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int. J. Clin. Pharmacol. Ther. (2004) 42(10):534-542.
   PubMed Web of Science ®Google Scholar
• KIM YC, JI XD, JACOBSON KA: Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J. Med. Chem. (1996) 39:4142-4148.
   PubMed Web of Science ®Google Scholar
• GALLO-RODRIGUEZ C, JI XD, MELMAN N et al.: Structure–activity relationships of N6-benzyladenosine-5′-uronamides as A3-selective adenosine agonists. J. Med. Chem. (1994) 37:636-646.
   PubMed Web of Science ®Google Scholar
• RATH-WOLFSON L, BAR-YEHUDA S, MADI L et al.: IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin. Exp. Rheumatol. (2006) 24(4):400-406.
   PubMed Web of Science ®Google Scholar
• PEREZ DM, KARNIK SS: Multiple signaling states of G-protein-coupled receptors. Pharmacol. Rev. (2005) 57(2):147-161.
   PubMed Web of Science ®Google Scholar
• KIM D, CHUNG J: Akt: versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol. (2002) 35(1):106-115.
   PubMedGoogle Scholar
• KIM G, JUN JB, ELKON KB: Necessary role of phosphatidylinositol 3-kinase in transforming growth factor β-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. (2002) 46(6):1504-1511.
   PubMed Web of Science ®Google Scholar
• MIYASHITA T, KAWAKAMI A, TAMAI M et al.: Akt is an endogenous inhibitor toward TNF-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem. Biophys. Res. Commun. (2003) 312(2):397-404.
   PubMed Web of Science ®Google Scholar
• OKAMOTO T: NF-κB and rheumatic diseases. Endocr. Metab. Immune Disord. Drug Targets (2006) 6:359-372.
   PubMedGoogle Scholar
• HANDEL ML, NGUYEN LQ, LEHMANN TP: Inhibition of transcription factors by anti-inflammatory and anti-rheumatic drugs: can variability in response be overcome? Clin. Exp. Pharmacol. Physiol. (2000) 27(3):139-144.
   PubMed Web of Science ®Google Scholar
• YIN H, CHENG H, YU M et al.: Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by down-regulating NF-κB activity. Immunol. Invest. (2005) 34:153-169.
   PubMed Web of Science ®Google Scholar
• POPE RM: Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. (2002) 2:527-535.
   PubMed Web of Science ®Google Scholar
• KRASILNIKOV MA: Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc.) (2000) 65(1):59-67.
   PubMed Web of Science ®Google Scholar
• WANG K, SCHEEL-TOELLNER D, WONG SH et al.: Inhibition of neutrophil apoptosis by Type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-d, and NF-κB signaling pathways. J. Immunol. (2003) 171(2):1035-1041.
   PubMed Web of Science ®Google Scholar
• PAP T, MULLER-LADNER U, GAY RE et al.: Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. (2000) 2(5):361-367.
   PubMedGoogle Scholar
• YANG KY, ARCAROLI J, KUPFNER J et al.: Involvement of phosphatidylinositol 3-kinase γ in neutrophil apoptosis. Cell Signal (2003) 15(2):225-233.
   PubMed Web of Science ®Google Scholar
• SSTOICA BA, MOVSESYAN VA, LEA PM et al.: Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3β, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol. Cell. Neurosci. (2003) 22(3):365-382.
   PubMed Web of Science ®Google Scholar
• STROBER S, HOLOSHITZ J: Mechanisms of immune injury in rheumatoid arthritis: evidence for the involvement of T cells and heat-shock protein. Immunol. Rev. (1990) 118:233-255.
   PubMed Web of Science ®Google Scholar
• VAN EDEN W, HOLOSHITZ J, NEVO Z et al.: Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc. Natl. Acad. Sci. USA (1985) 82:5117-5120.
   PubMed Web of Science ®Google Scholar
• TAUROG JD, SANDBERG GP, MAHOWALD ML: The cellular basis of adjuvant arthritis. II. Characterization of the cells mediating passive transfer. Cell Immunol. (1983) 80(1):198-204.
   PubMed Web of Science ®Google Scholar
• SPARGO LD, CLELAND LG, COCKSHELL MP et al.: Recruitment and proliferation of CD4+ T cells in synovium following adoptive transfer of adjuvant-induced arthritis. Int. Immunol. (2006) 18(6):897-910.
   PubMed Web of Science ®Google Scholar
• SWIERKOT J, SZECHINSKI J: Methotrexate in rheumatoid arthritis. Pharmacol. Rep. (2006) 58(4):473-492.
   PubMed Web of Science ®Google Scholar
• CHAN L, CRONSTEIN BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res. (2002) 4(4):266-273.
   PubMedGoogle Scholar
• BAGGOT JE, MORGAN SL, SAMS WM et al.: Urinary adenosine and aminoimidazolcarboxamide excretion in methotrexate-treated patients with psoriasis. Arch. Dermatol. (1999) 135(7):813-817.
   PubMed Web of Science ®Google Scholar
• LAGHI PASINI F, CAPECCHI PL, DI PERRI T: Adenosine plasma levels after low-dose methotrexate administration. J. Rheumatol. (1997) 24(12):2492-2493.
   Google Scholar
• OCHAION A, BAR-YEHUD S, COHEN S et al.: Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res. Ther. (2006) 8(6):R169.
   PubMed Web of Science ®Google Scholar
• HARRIS ED: Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. (1990) 322(18):1277-1289.
   PubMed Web of Science ®Google Scholar
• PEREZ-EDO L, DIEZ-PEREZ A, MARINOSO L et al.: Bone metabolism and histomorphometric changes in rheumatoid arthritis. Scand. Rheumatol. (2002) 31(5):285-290.
   PubMed Web of Science ®Google Scholar
• RODAN GA, MARTIN TJ: Therapeutic approaches to bone diseases. Science (2000) 289(5484):1508-1514.
   PubMed Web of Science ®Google Scholar
• HSU H, LACEY DL, DUNSTAN CR et al.: TNF receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA (1999) 96(7):3540-3545.
   PubMed Web of Science ®Google Scholar
• KONG YY, FEIGE U, SAROSI I et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 402(6759):304-309.
   PubMed Web of Science ®Google Scholar
• HOFBAUER LC, LACEY DL, DUNSTAN CR et al.: Interleukin-1β and TNF-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 25(3):255-259.
   PubMed Web of Science ®Google Scholar
• WALSH NC, GRAVALLESE EM: Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr. Opin. Rheumatol. (2004) 16(4):419-427.
   PubMed Web of Science ®Google Scholar
• MABLEY J, SORIANO F, PACHER P et al.: The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. (2003) 466:323-329.
   PubMed Web of Science ®Google Scholar
• GUZMAN J, YU JG, SUNTRES Z et al.: ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm. Bowel Dis. (2006) 12:766-789.
   PubMed Web of Science ®Google Scholar
• HASKO G, NEMETH ZH, VIZI ES, SALZMAN AL, SZABO C: An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur. J. Pharmacol. (1998) 358:261-268.
   Google Scholar
• LEE HT, KIM M, JOO JD, GALLOS G, CHEN JF, EMALA CW: A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) 291:R959-R969.
   PubMed Web of Science ®Google Scholar
• SILVERMAN MH, STRAND V, MARKOVITS D et al.: Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a Phase II clinical trial. J. Rheumatol. (2007) (Accepted).
   Google Scholar
• LAPPAS CM, SULLIVAN GW, LINDEN J: Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs (2005) 14(7):797-806.
   PubMed Web of Science ®Google Scholar
• DHALLA AK, WONGMY, WANG WQ, BIAGGIONI I, BELARDINELLI L: Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J. Pharmacol. Exp. Ther. (2006) 316:695-702.
   PubMed Web of Science ®Google Scholar
• VAN EDE AE, LAAN RF, BLOM HJ, DE ABREU RA, VAN DE PUTTE LB: Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin. Arthritis Rheum. (1998) 27:277-292.
   PubMed Web of Science ®Google Scholar
• MADDISON P, KIELY P, KIRKHAM B et al.: Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (2005) 44:280-286.
   PubMed Web of Science ®Google Scholar
• GREMESE E, FERRACCIOLI GF: Benefit/risk of cyclosporine in rheumatoid arthritis. Clin. Exp. Rheumatol. (2004) 22:S101-S107.
   PubMed Web of Science ®Google Scholar
• MARRA CA, ESDAILE JM, GUH D et al.: The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum. (2001) 45:240-245.
   PubMed Web of Science ®Google Scholar
• WINTHROP KL: Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of TNF. Nat. Clin. Pract. Rheumatol. (2006) 2:602-610.
   PubMedGoogle Scholar
• DESAI SB, FURST DE: Problems encountered during anti-TNF therapy. Best Pract. Res. Clin. Rheumatol. (2006) 20:757-790.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF: B cell targeted therapies: safety considerations. J. Rheumatol. Suppl. (2006) 77:18-23.
   PubMedGoogle Scholar
• PEIFER C, WAGNER G, LAUFER S: New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. (2006) 6:113-149.
   PubMed Web of Science ®Google Scholar